Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06361888 | A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | PHASE2 | RECRUITING | 502 | — | — | May 8, 2024 | May 31, 2028 | May 28, 2026 | 2 | China |
Duration from the date of initial treatment to the date of death due to any cause
| Arm | Type | Description |
|---|---|---|
| Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | EXPERIMENTAL | - |
| Nab-paclitaxel Plus Gemcitabine | ACTIVE_COMPARATOR | - |
| Surufatinib with Nab-paclitaxel, and Gemcitabine | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | DRUG | Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine 1. Surufatinib: 200mg, qd 2. Camrelizumab: 200mg, IV drip, Q3W, D1 3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8 |
| Nab-paclitaxel Plus Gemcitabine | DRUG | Drug: Nab-paclitaxel Plus Gemcitabine 1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8 |
| Surufatinib with Nab-paclitaxel, and Gemcitabine | DRUG | Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine 1. Surufatinib: 200mg, qd 2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8 |
Inclusion Criteria: 1. Fully understand and voluntarily sign an informed consent form, willing and able to follow the study process; 2. Age range is 18-75 years old (inclusive); 3. Pancreatic cancer confirmed by histology or cytology; 4. Stage IV metastasis Pancreatic cancer patients; 5. Have not r...